Cannabis and obesity
Browse the latest research linking medical marijuana / medicinal cannabis and obesity.

See also: weight loss 
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
WIN55,AM6545 weight loss,obesity in mice via experiment Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity Mar 2019
Action Pathway: CB1
Collectively, these results provide evidence that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-mediated inhibition of gut-brain satiation signaling.
AM6545 obesity in mice Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity Aug 2010
Action Pathway: CB1
Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause weight-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile
AM6545 obesity,appetite supress in vitro A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents Oct 2010
Peripherally active, cannabinoid receptor antagonists with limited brain penetration may be useful agents for the treatment of obesity and its complications.
AM6545 obesity,appetite supress in rats via experiment THE NOVEL CANNABINOID CB1 ANTAGONIST AM6545 SUPPRESSES FOOD INTAKE AND FOOD-REINFORCED BEHAVIOR Aug 2010
Ingestion Method: 16mg/kg
AM6545 also produced a strong suppression of the intake of high carbohydrate and high fat diets in the same dose range, but only produced a mild suppression of lab chow intake at the highest dose (16.0 mg/kg). Although AM6545 did not affect food handling, it did reduce time spent feeding and feeding rate. Taken together, these results suggest that AM6545 is a compound that warrants further study as a potential appetite suppressant drug.
cannabinoids pain,addiction,obesity via article Cannabinoids: Friend or Foe? Jun 2016
These are interesting time for cannabinoid research and clinical application; much more needs to be done to translate the potential of cannabinoid drugs to medicinal use and to identify the conditions that could benefit from this class of drugs. There is as yet untapped potential in the areas of pain and addiction, obesity, metabolic syndrome and epilepsy
cannabis obesity,diabetes in humans via survey (n=786) Cannabis use in relation to obesity and insulin resistance in the Inuit population. Feb 2015
Positive  Cannabis use was highly prevalent in the study population (57.4%) and was statistically associated with lower body mass index (BMI) (P < 0.001), lower % fat mass (P < 0.001), lower fasting insulin (P = 0.04), and lower HOMA-IR (P = 0.01), after adjusting for numerous confounding variables. Further adjustment for BMI rendered fasting insulin and HOMA-IR differences statistically nonsignificant between past-year cannabis users and nonusers. Mediation analysis showed that the effect of cannabis use on insulin resistance was indirect, through BMI.
Cymene obesity,diabetes in mice (n=48) Cymene and Metformin treatment effect on biochemical parameters of male NMRI mice fed with high fat diet. June 2015
Non-fasting glucose serum levels, ALT, and ALP of E2 and E3 decreased significantly compared to HFD control group.
CBD obesity,weight loss in rats via experiment Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents Jun 2019
Ingestion Method: 10, 20, and 40 mg/kg, ip
Action Pathway: CB1,CB2
Taken together, the present findings suggest that CBD may have therapeutic potential in reducing binge eating and the development of obesity.